• Minoli Perera

    The Perera Lab

     

    Associate Professor

    Northwestern University

  • The Perera laboratory focuses on pharmacogenomics (using a patient's genome to predict drug response) in minority populations. Our goal is to make precision medicine available to all.

    Dr. Minoli Perera PharmD, PhD

    Dr. Perera is an Associate Professor within the Department of Pharmacology and Center for Pharmacogenomics at the Feinberg School of Medicine with expertise in pharmacokinetics, clinical pharmacology and human genetics.

  • What We Do

    African American Genomic Medicine

    Anticoagulant Pharmacogenomics Perera Lab

    Anticoagulant Pharmacogenomics

    Prescribing the right drug at the right dose for the right patient

    Anticoagulants remain some of the most dangerous drugs taken in the US. We investigate if a patient's genome can predict the therapeutic dose, or adverse effects (e.g. bleeding) associated with these drugs. This information could be used to help doctors select the safest and most effective medication for each patient.

    Genomics of Drug Metabolism Perera Lab

    Genomics of Drug Metabolism

    Genetic biomarkers that regulate drug metabolism

    The liver metabolizes over 70% of drugs currently prescribed in the US. However, we still do not understand the genes and genetic mutations that regulate these important hepatic enzymes. We are investigating the role of genetic variation in the regulation of gene expression of drug metabolizing enzymes (DMEs) in African Americans (funded NIMDH). Click here for details on this project.

    Pharmacogenomics of Inflammatory Bowel Disease Perera Lab

    Pharmacogenomics of Inflammatory Bowel Disease  

    Genetic biomarkers to predict primary non-response.

    Biologic therapies have been a revolution in the treatment of inflammatory bowel disease. However there remains a subset of patients that do not respond to these drugs and hence receive no clinical benefit. Moreover, this subset will be exposed to potential side-effects from biologic therapy. Genetic biomarkers that can predict if a patient will respond to biologic therapy would enable physicians to make better decision for patients and limit unwanted drug exposure to those with little chance of benefit.

    eMERGE

    Using the electronic health record to personalize healthcare.

    The Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The Network brings together researchers with a wide range of expertise in genomics, statistics, ethics, informatics, and clinical medicine from leading medical research institutions across the country to conduct research in genomics, including discovery, clinical implementation and public resources. we are involved in the analysis on the newest eMERGE sequencing data. We hope to identify novel variants in genes important to drug response.

    ACCOuNT

    African American Cardiovascular Pharmacogenomics Consortium

    ACCOuNT is a NIMHD funded Collaborative Consortium aimed at accerateing the pace of pharmacogenomic discovery and translation in African Americans. We have brought together investigators at 2 major US cities (Chicago and DC), as well as clinical, pharmacogenomic and informatics experts to build a sustainable research consortium. Click here for more details. We have also been featured in PGRN HUB.

  • Profiles

    Meet the Lab

    Lab Manager

    Cristina is a PhD scientist who keep our lab running smoothly. She is involved in all aspect of our lab, from organization to methods development.

    Paula Frienman Perera Lab

    Senior Research Associate

    Dr. Friedman has worked extensively in cancer genomics and pharmacogenomics prior to joining the lab. She is currently managing the projects associated with the ACCOuNT Consortium.

    Tanima De Perera Lab

    Postdoctoral Scolar

    Dr. De is a Postdoctoral scholar working on genetic regulation of hepatic drug metabolism and bleeding risk biomarker identification.

    Bioinformatics Analyst

    Dr. Xu has specific expertise in RNA-seq gene expression analysis. She has jumped into the role of our "go-to" computational expert.

    Jamie Brewer Perera Lab

    Hem/Onc Fellow

    Dr. Brewer is interested in cancer health disparities. She is investigating the genetic predictors of thrombosis in cancer.

    Wenndy Hernandez Perera Lab

    F32 Postdoctoral Fellow

    Dr. Hernandez is a PhD graduate of the University of Chicago working on genomic predictors on thrombosis and anticoagulant response.

    Wenndy Hernandez Perera Lab

    Bioinformatics Graduate Student

    Yizhen joined our lab in July 2016. She is interested in developing methods for incorporating estimates of ancestry into eQTL analysis.

  • Past Lab members

    Off to bigger and better things!

    Graduate Student

    Nneka Nwanze

    Keston Aquino-Michaels - Data Scientist at SparkBeyond.

    Erin Smithberger - Graduate student at University of North Carolina

    Undergraduate student

    Ijezie Ikwuezunma - Senior at Washington and Lee Univeristy and winner of the Johnson Opportunity Grant

    Sara Kwan

    Minnie Horvath

    Riean Knight

    Stephanie Poindexter - Graduate Student in Anthropology, Oxford Brooks University

    Megan Flynn - Georgetown Medical student

    Medical/Pharmacy students

    Lucia Cortejoso - PharmD in Hospital General Univeritario, Spain

    Mary Young - Medical Resident

    High School students

    Maggie Colten

  • Recent Publications

    Find a full list of our publications here

    Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clin Pharmacol Ther. 2017 Feb 15 (epub ahead of print).

     

    Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. Hernandez W, Gamazon ER, Aquino-Michaels K, Smithberger E, Patel S, O’Brien TJ, Harralson AF, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Konkashbaev A, Cavallari LH, Perera MA. J Thromb. Haemost. 2017 Jan 30 (epub ahead of print)

     

    Population Differences in the Pharmacokinetics of S-warfarin Among African Americans, Asians and Caucasians: Implications for Pharmacogenetic Dosing Algorithms. Kubo K, Ohara M, Tachikawa M, Cavallari LH, Lee MTM, Scordo MG, Nutescu E, Perera MA, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen YT, Yakahashi H. Pharmacogenomics J. 2016 June; 4(5):513-520

     

    Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Nagai R, Ohara M, Cavallari LH, Drozda K, Patel SR, Nutescu EA, Perera MA, Hernandez W, Kaneko N, Hibiya M, Takahashi H. Pharmacogenomics. 2015 Mar; 2016(3):217-25.

     

    Population specific genomics identifies predictor of Venous Thromboembolism in African Americans. Hernandez W, Gamazon ER, Smithberger E, O’Brien T, Harrelson A, Tuck M, Barbour A, Kittles RA, Cavallari LH, Perera MA. Blood 2016 Apr. 14; 127(15): 1923-1929. Press Release by American Society of Hematology, Commentary in Blood 127 (15).

     

    Population-specific single nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. Daneshjou R, Cavallari LH, Weeke PE, Karczewski KJ, Drozda K, Perera MA, Johnson J, Klein TE, Bustamante CD, Roden D, Shaffer C, Denny JC, Zehnder JL, Altman RB. Molecular Genetics &Genomic Medicine 2016 Jun 21;4(5):513-520

     

  • The Perera Lab Blog

    Thoughts, musings, and ruminations.

  • Collaborators/Consortiums

    We could all use a little help from our friends.

    Larisa Cavallari Perera Lab

    Larisa Cavallari

    University of Florida

    Travis O'Brien Perera Lab

    George Washington University

    Director of the Pharmacogenomics Program and Associate Research Professor of Pharmacology and Physiology

    Julio Duarte Perera Lab

    Julio Duarte

    University of Illinois, Chicago

    Director, Pharmacogenomics Laboratory, Pharmacy Practice

    Pharmacogenomics Research Network

    The PGRN catalyzed pharmacogenomics discoveries both nationally and internationally through the conduct of collaborative research focused on the discovery and translation of the genetic determinants of drug response, in order to enable safer and more effective drug therapies.

    PGRN-CGM

    A collaboration to further Precision medicine 

    Leaders at the National Institutes of Health(NIH) Pharmagenomics Research Network (PGRN) and the RIKEN Center for Genomic Medicine(CGM) in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics. Using genomewide approaches, identify genetic variants that contribute to individual responses to medicines, including rare and serious side effects. 

  • Official Lab Photo

    Perera Lab

    Lab Photo Fall 2016

    Northwestern University Downtown Quad

  • Contact Information

    Minoli Perera Linkin
  • CONTACT US! 

All Posts
×